The U.S. Food and Drug Administration's reviewers on Wednesday raised efficacy concerns over the use of Otsuka Pharma's drug ...

An FDA advisory panel concludes that the efficacy of brexpiprazole, when started concurrently with sertraline, has not been ...

The U.S. Food and Drug Administration's panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma's ...

This summary covers significant health news including FDA advisers rejecting Otsuka's PTSD treatment, Getinge exceeding ...

The FDA staffers on Wednesday cited efficacy issues related to a combination regimen involving brexpiprazole, an antipsychotic medication developed by Otsuka Pharma (OTCPK:OTSKY) and H. Lundbeck ...

Otsuka and Lundbeck’s data are insufficient to establish significant efficacy of Rexulti plus sertraline in PTSD, according ...

The FDA panel voted against Otsuka's PTSD drug combination with Zoloft, questioning its efficacy. Getinge surpassed profit ...

June 05, 2024 FDA advisory panel votes against MDMA for treatment of PTSD Concerns about the safety of the psychedelic drug and the way studies were conducted led to the decision.

FDA advisers voted 10-1 against the overall benefits of using MDMA to treat PTSD, citing flawed study data, questionable research conduct. Advocates and scientists say those who received doses of ...

The FDA rejected an application for the drug MDMA, in combination with therapy, as treatment for PTSD on Friday. 24/7 Live Raleigh Durham Fayetteville Surrounding Area Welcome, Mickey ...

A panel of advisers to the FDA voted against the potential use of MDMA for treating PTSD. Skip to content. TV 8 | News 88.7 | Classical | Mixtape. November 05, 2024. 65 °F.

The U.S. Food and Drug Administration's reviewers have raised efficacy concerns over Otsuka Pharma's combination drug for ...